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ABSTRACT
Introduction: In order to provide baseline data on
genetic testing as a key element of personalised
medicine (PM), Canadian physicians were surveyed to
determine roles, perceptions and experiences in this
area. The survey measured attitudes, practice,
observed beneﬁts and impacts, and barriers to
adoption.
Methods: A self-administered survey was provided to
Canadian oncologists, cardiologists and family
physicians and responses were obtained online, by
mail or by fax. The survey was designed to be
exploratory. Data were compared across specialties
and geography.
Results: The overall response rate was 8.3%. Of the
respondents, 43%, 30% and 27% were family
physicians, cardiologists and oncologists, respectively.
A strong majority of respondents agreed that genetic
testing and PM can have a positive impact on their
practice; however, only 51% agreed that there is
sufﬁcient evidence to order such tests. A low
percentage of respondents felt that they were
sufﬁciently informed and conﬁdent practicing in this
area, although many reported that genetic tests they
have ordered have beneﬁted their patients. Half of the
respondents agreed that genetic tests that would be
useful in their practice are not readily available. A lack
of practice guidelines, limited provider knowledge and
lack of evidence-based clinical information were cited
as the main barriers to practice. Differences across
provinces were observed for measures relating to
access to testing and the state of practice. Differences
across specialties were observed for the state of
practice, reported beneﬁts and access to testing.
Conclusions: Canadian physicians recognise the
beneﬁts of genetic testing and PM; however, they lack
the education, information and support needed to
practice effectively in this area. Variability in practice
and access to testing across specialties and across
Canada was observed. These results support a need
for national strategies and resources to facilitate
physician knowledge, training and practice in PM.
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ARTICLE SUMMARY
Article focus
- Canadian physicians’ perceptions and experience
relating to genetic testing and personalised
medicine (PM).
- Practice and impact of genetic testing and PM in
Canada and across specialties.
- Implications for continued adoption of genetic
testing and PM in Canada across specialties.
Key messages
- Family physicians, cardiologists and oncologists
across Canada are practicing PM and recognise
its beneﬁts and potential impacts.
- Physicians reported a number of barriers to the
adoption of PM that are currently affecting
medical practice in Canada.
- The practice of and access to genetic testing and
PM varies across specialties and provinces,
which will have an impact on their continued
adoption.
Strengths and limitations of this study
- First national survey of physicians on this topic
- Allows for a baseline measure of practice for
comparison in future studies
- Medical discipline speciﬁc study
- Administration of the survey over the period 26
May to 15 September 2010 may have negatively
inﬂuenced the response rate.
- There may have been differences in respondents
based on the medium used to complete the survey
(electronic vs paper-based).
- The topic of genetic testing and personalised
medicine may not have been relevant to all
physicians who were sent the survey, which may
have negatively affected the response rate.
- All survey results were based on physicians’ self-
reports.
- The physician contact information was
purchased through a third party and some data
were incomplete or inaccurate.
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Open Access ResearchINTRODUCTION
. for the sweet ones [treatments] do not beneﬁt
everyone, nor do the astringent ones, nor are all the
patients able to drink the same things. (Hippocrates)
Personalised medicine (PM), the tailoring of medical
treatment or prevention to the individual characteristics
of each patient, has been enabled by recent advances in
molecular biology.
1 Research in the ‘-omic’ sciences has
resulted in improved understanding of the relationships
between genes, proteins and disease, providing more
tools for PM
2e5 and driving a shift in medical practice.
6
Evidence of this ‘shift’ includes a 66% increase in
cancer-related genetic testing in Ontario between 2002
and 2008,
7 and the facts that 10% of FDA approved
drugs include pharmacogenomic information on their
labels
8 and genetic testing is recommended or required
for at least 11 FDA approved drugs
9 and for 10 Health
Canada approved drugs (based on a review of drug
labelling using the Health Canada Drug Product Data-
base). A number of applications of PM based on genetic
testing are currently in use.
10 Pharmacogenomics, the
optimisation of drug therapy based on genetic infor-
mation, has been applied to improve clinical outcomes
or reduce side effects and adverse events.
11 12 Targeted
therapeutics, used in combination with companion
diagnostics, has been particularly successful in
improving treatment for cancer.
13 14 Finally, PM is being
used to assess disease risk, facilitating prevention and
early detection.
15
As a result of these developments, PM has become an
increasingly important topic for physicians, healthcare
organisations and the public.
16 17 There is widespread
debate concerning the intended and unintended conse-
quences of PM for the quality and cost of healthcare;
many scientiﬁc and medical leaders expect PM to increase
the quality of healthcare and reduce overall healthcare
costs.
13 18 19 A few studies have assessed the adoption of
genetic testing and its impact on the role and practice of
physicians in Canada.
20e24 These studies focused
primarily on the adoption of genetic tests for the diag-
nosis and treatment of cancer within Ontario’s healthcare
system, and recommended physician education, public
education and improved coordination of healthcare
delivery and genetic testing services. In order to facilitate
medical and continuing professional education in PM in
Canada, it is essential to have a baseline understanding of
current knowledge, attitudes and practices.
The present pan-Canadian survey of practicing oncol-
ogists, cardiologists and family doctors was designed to
provide baseline data on genetic testing as a key element
of PM in Canada regarding attitudes, state of practice
and barriers to adoption. Three specialties were targeted
in the survey: cardiologists and oncologists as they
experience higher volumes and greater need for
personalised genetic testing, and family physicians as
they are usually the ﬁrst point of contact for patients and
are often involved in screening for risk of disease.
METHODS
Ethics approval was received from IRB Services to survey
a sample of Canadian physicians (oncologists, cardiologists
and family physicians) regarding their knowledge, training
and practice in genetic testing and PM.
Physician contact information was obtained from
a third party for 859 oncologists and 1165 cardiologists
from across Canada. A weighted sample, based on
population, of family physicians (n¼2334) from Cana-
dian provinces was randomly selected from contacts with
email addresses. The self-administered survey was avail-
able in French and English and distributed by mail, fax
and email during the period 26 May to 15 September
2010. Respondents submitted their responses online, by
mail or by fax. Survey candidates were contacted with up
to four reminders to encourage participation. The
survey questions related to demographic information,
training, practice, knowledge and education in PM
based on genetic testing, the nature and extent of
practice in this area, and the beneﬁts of PM and barriers
to its adoption. Questions were developed based on the
authors’ knowledge of genetic testing and PM. A draft of
the survey questions was developed based on this
knowledge and a review of the literature of previous
surveys conducted in other jurisdictions.
25 26 This draft
survey was subsequently reviewed by 11 physicians (ﬁve
oncologists, three cardiologists and three family physi-
cians) and their feedback was incorporated into the
ﬁnal survey. The survey’s design was informed by how
new technologies or innovations are adopted in practice
and a diffusion of innovations framework was consid-
ered.
27 The survey solicited physicians’ knowledge of,
attitudes towards and practice of personalised genetic
testing to understand the relative advantages, compati-
bility, ease of implementation and system response to
adoption of personalised genetic testing. This is an
initial application of this framework to the Canadian
context.
Vovici software
28 was used for the online survey
administration, allowing for both open-ended and close-
ended questions, and menu creation for selection of pre-
determined answer options for close-ended questions. All
questionnaires were reviewed for completeness. The data
entry protocol included separate quality review of each
survey against the entered data to ensure accuracy. Survey
results were analysed using STATA software v 11.0.
29
This study was designed to be exploratory and
included analyses based on descriptive statistics and
bivariate associations. Inferential analyses were not
pursued. Answers to survey questions were compared
according to medical specialty and region or province.
Fewer responses were received from the Atlantic prov-
inces, Saskatchewan, Manitoba and Alberta compared to
Ontario, Quebec and British Columbia. Data from the
Atlantic provinces (Nova Scotia, New Brunswick,
Newfoundland and Prince Edward Island) were
combined and data from Saskatchewan, Manitoba and
Alberta were combined.
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questions, results with more than a 5% probability of
occurring by chance were excluded. Pearson c
2 test
statistics were calculated to determine whether differ-
ences according to medical specialty, region or province
were statistically signiﬁcant.
RESULTS
Respondent proﬁle
A total of 363 physicians provided responses to the
survey (8.3% overall response rate). Physicians not
providing direct patient care (n¼16) or not practicing
family medicine, cardiology or oncology (n¼6) were
excluded. Thus, the respondent group retained for the
analysis comprised 341 active physicians with an adjusted
response rate of 9.7%.
Of the respondents, 43%, 30% and 27% were family
physicians, cardiologists and oncologists, respectively.
Thirty-three per cent of the respondents practiced in
Ontario, 20% in Quebec, 24% in Manitoba, Saskatchewan
and Alberta, 14% in the Atlantic provinces and 9% in
British Columbia. Of the cardiologist and oncologist
respondents, 73% and 79%, respectively, held academic
appointments, compared to 41% of family physician
respondents. One-third of survey respondents were in the
46e55 age range. The average time since completion of
training was 12 years for participating oncologists,
18 years for cardiologists and 22 years for family physi-
cians. Family physician respondents reported working
predominantly in ofﬁces or clinics, cardiologists
predominantly in academic health science centres,
community hospitals and private ofﬁces/clinics, and
oncologists predominantly in academic health sciences
centres. Respondents from all specialties were repre-
sented in each geographical area as shown in ﬁgure 1.
Attitudes and perceptions
Respondents were asked a series of questions about their
attitudes and perceptions regarding the usefulness of
genetic testing in the context of PM, as an indicator of
physicians’ openness to the adoption of PM. The
majority of respondents agreed that knowing a patient’s
genetic proﬁle can inﬂuence treatment decision-making
(83%) and importantly, can improve patient outcomes
(70%). However, only 51% of respondents agreed that
there is sufﬁcient evidence to support ordering genetic
tests. The perception of the usefulness of genetic testing
was similar across specialties and provinces as no
signiﬁcant differences were observed (ﬁgure 2).
State of practice
Respondents’ current levels of practice and knowledge
of genetic testing and PM were also assessed. The results
indicate that oncologist respondents are practicing more
PM, with 59% reporting having ordered a genetic test in
the past month compared to only 22% of general prac-
titioners and cardiologists. Oncologists also reported
feeling more informed, more able to interpret test
results and more comfortable discussing results with
patients compared with other specialties (ﬁgure 3).
Overall, only 21% of respondents agreed that they are
sufﬁciently informed about PM and 29% agreed that
they are able to interpret the results of genetic tests.
Thirty per cent of respondents agreed that they are
comfortable discussing test results with patients. These
Figure 1 Distribution of respondents by specialty: family
medicine (Fam.), cardiology (Card.) and oncology (Onco.) and
by geography: Ontario (ON), Quebec (QC), British Columbia
(BC), Western Provinces (WST) and Atlantic provinces (ALT).
Figure 2 Respondent’s perceptions of utility by speciality
(panel A): family medicine (Fam.), cardiology (Card.) and
oncology (Onco.) and by geography (panel B): Ontario (ON),
Quebec (QC), British Columbia (BC), Western provinces
(WST) and Atlantic provinces (ALT).
Figure 3 Measures of state of practice by specialty (panel A):
family medicine (Fam.), cardiology (Card.) and oncology
(Onco.) and by geography (panel B): Ontario (ON), Quebec
(QC), British Columbia (BC), Western provinces (WST) and
Atlantic provinces (ALT). GT, genetic test; PM, personalised
medicine.
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(ﬁgure 3). The survey also assessed physicians’ percep-
tions of the impact of genetic testing on their patients.
Of the respondents, 40% agreed that their patients have
expressed fears of discrimination based on genetic
testing and 37% reported that their patients are asking
them about genetic testing and PM. Similar reports of
patients expressing fear of discrimination were observed
across specialties (ﬁgure 3); however, more oncologists
(50%) reported that patients are asking about
PM compared to 30% of cardiologists and 32% of
general/family physicians (ﬁgure 3).
Impacts and beneﬁts
Respondents were asked a series of questions about the
impact and beneﬁts of genetic testing for their practices.
Most respondents reported that genetic tests they
ordered were to identify a genetic predisposition or risk
factor (60% agreed vs 20% disagreed) and that these
tests inﬂuenced patient treatment plans (54% agreed vs
18% disagreed). Many also reported that genetic tests
they ordered increased the therapeutic beneﬁt for
patients (42% agreed vs 19% disagreed). Comparing
across specialties (ﬁgure 4, panel A), oncologist
respondents were more likely to agree that tests they had
ordered had inﬂuenced treatment plans (67% agreed)
compared to other specialties (c
2 p¼0.006). Note that
for the purpose of this study, ‘ordering’ means either
requisitioning a test directly or facilitating access
through another healthcare professional, such as
a medical geneticist or other specialist (56% of respon-
dents reported that they are responsible for ordering
genetic tests for their patients and 31% reported that
a geneticist is responsible for ordering tests for their
patients).
Barriers to adoption
Respondents were asked to indicate what they perceive
as the main barriers to their practice of genetic testing
and PM. A list of 13 barriers (table 1) was provided. The
top ﬁve cited barriers were: lack of clinical practice
guidelines, limited provider knowledge, attitudes and
awareness of beneﬁts, lack of evidence-based clinical
information, the cost of testing and a lack of time and
resources to educate patients.
Access to testing
With regards to access to appropriate genetic testing for
their patients, 50% of respondents agreed that tests
which they believe would be useful in their practice are
not readily available, 48% indicated that the cost of
genetic tests is a main barrier to the use of PM and 33%
indicated that the length of time it takes to obtain results
is an important barrier to the use of PM, as the results
may not be received in time to help make treatment
decisions. Compared to other specialities, oncologists
identiﬁed the time it takes to obtain results as a barrier
to practice (59%) more often than other specialties
(ﬁgure 5, panel A). In general, these measures relating
Figure 4 Comparison of reported impacts and beneﬁts by
specialty (panel A): family medicine (Fam.), cardiology (Card.)
and oncology (Onco.) and by geography (panel B): Ontario
(ON), Quebec (QC), British Columbia (BC), Western Provinces
(WST) and Atlantic provinces (ALT). ID, identiﬁed.
Table 1 Barriers to adoption
Barriers to physicians
ordering genetic tests for
personalised medicine
% Of respondents
who cited barrier
as a ‘main barrier’
Lack of clinical guidelines 60
Limited provider knowledge,
awareness
57
Lack of evidence-based
clinical information
53
Cost of tests is prohibitive 48
Lack of time, resources to
educate patients
37
Results take too long for a
treatment decision
33
Too much paperwork/bureaucracy 31
Lack of insurance coverage 28
Insufﬁcient regulatory framework 27
Patient anxiety regarding test results 24
Lack of reimbursement 19
Approval process takes too long 14
Test results will not affect treatment 13
Figure 5 Measures of barriers to access by speciality (panel
A): family medicine (Fam.), cardiology (Card.) and oncology
(Onco.) and by geography (panel B): Ontario (ON), Quebec
(QC), British Columbia (BC), Western provinces (WST) and
Atlantic provinces (ALT).
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reﬂecting differences in access to genetic testing across
Canada (ﬁgure 5, panel B).
Physician education
Most respondents reported (ﬁgure 6) having no formal
undergraduate (92%) or graduate training (89%) in
genetic testing and PM. Interestingly, 73% of respon-
dents have attended university lectures or engaged in
self-study and 75% would like more continuing educa-
tion in this area. More oncologists reported having
graduate training in this area (27%) compared to the
other specialties (c
2 p¼0.0001).
DISCUSSION
Attitudes, impacts and beneﬁts
The results of this study indicate that Canadian physi-
cians responding to the survey are optimistic about the
promise of PM, and open to its use. The majority of
respondents agreed that genetic testing as a component
of PM can inﬂuence treatment plans (83%) and improve
outcomes (70%). This is consistent with a recent survey
of molecular oncology testing in Ontario, where it was
reported that molecular oncology testing is expected to
become increasingly prevalent in all areas of diagnosis,
prognosis and treatment in the foreseeable future.
21
Similar ﬁndings from another Canadian survey
30 and
a study of over 10000 physicians in the US
25 also indicate
widespread awareness among physicians of the current
value and potential impact of PM. The positive percep-
tions found among Canadian physician respondents may
facilitate efﬁcient and appropriate adoption of PM into
practice.
Patient engagement has been identiﬁed as a possible
factor in physicians’ attitudes towards adopting new
practices.
26 31 Thirty-seven per cent of respondents
reported that their patients were enquiring about
genetic testing and PM. Physicians also reported that
patients expressed fear of discrimination based on
genetic testing (ﬁgure 3). Although Canadian law does
not speciﬁcally prohibit genetic discrimination, a level of
protection is provided by the Canadian Human Rights
Act (Art. 3) and the Personal Information Protection
and Electronic Documents Act. Steps have been taken to
strengthen these protections. In April 2010, Bill C-508,
an act to amend the Canadian Human Rights Act to
specify genetic discrimination, was introduced into
parliament.
32 Few respondents indicated that patient
anxiety concerning test results is a barrier (table 1). This
is consistent with a recent US study of more than 2000
individuals which found no post-test anxiety or adverse
outcomes in individuals who received comprehensive
genetic proﬁling.
33
State of practice
This study showed that oncologists are practicing more
in this area (ﬁgures 3 and 4) and are leading in terms of
adoption of PM among the specialties surveyed. With
regards to access to testing, it was found that this and
other measures of the state of practice across the prov-
inces varied (ﬁgure 5). This variability in practice and
access across Canada may be due to differences in access
to testing services, funding and the interpretation of the
evidence or perception of beneﬁts from province to
province. It has been suggested that decision-making
related to predictive genetic testing is ad hoc and vari-
able across Canada and that a coordinated national
approach is needed.
23 Recommendations have been
proposed for a coordinated approach to the adoption
and funding of genetic testing in Ontario.
34 Work in this
area is critical to ensuring equitable access and
improving parity of healthcare across Canada. A coor-
dinated strategy and implementation across the country
may be challenging given the disparate provincially
funded and controlled healthcare systems in Canada.
Barriers to adoption
A lack of medical guidelines was identiﬁed by respon-
dents (61%) as the predominant barrier to adoption,
indicating a need for the development of best practices
and guidelines to support the implementation of PM.
Sharing of best practices as well as genetic testing and
pharmacoeconomic information across provincial
healthcare systems is also likely necessary to support
efﬁcient and cost-effective national implementation of
PM.
Of the respondents, 62% agreed that medical infor-
matics will be critical to delivering PM. Indeed, vast
amounts of data will be generated with widespread
adoption, and an IT infrastructure for collection,
storage, analysis, interpretation and reporting will be
needed.
35e37 Furthermore, decision support tools,
including electronic medical records, will be needed to
facilitate interpretation and point-of-care decision-
making. This may pose a signiﬁcant barrier in Canada
where IT infrastructure and electronic medical record
implementation is targeted for completion only in
2015,
38 signiﬁcantly later than in other OECD nations.
Surveys of Canadian
21 22 and US physicians
25 have
reported the need for physician education for the
successful adoption of PM. These studies found that
a majority of physicians lack the education, training and
Figure 6 Measures of physician education in genetic testing
and personalised medicine by speciality.
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study supports these ﬁndings. Furthermore, respondents
indicated that they are actively pursuing more informa-
tion, with 73% engaging in self-study. These data support
a need for formal and continuing physician education in
this area. A 2010 survey of 90 medical schools in the US
and Canada found that 80% have begun to incorporate
pharmacogenomic training into their curricula;
however, approximately 60% considered this instruction
at their school to be ‘poor’ and more than 80% were not
considering increasing the level of instruction within the
next 3 years.
39
Physicians’ perceptions and knowledge of the evidence
supporting the clinical and analytical validity of genetic
tests for PM are obviously important for its adoption.
Canadian and US studies have demonstrated that current
physician knowledge, real-world data and guidelines
relating to PM have often been insufﬁcient for appro-
priate adoption,
40 even where testing is recommended or
publicly funded.
41 42 In the present study, 51% of
respondents agreed that there is sufﬁcient evidence to
order genetic tests for PM. These results suggest either
a need for better physician education or a need for
additional supporting evidence for PM implementation.
Most likely both factors are at play. Further supporting
the need for more research was the ﬁnding that 53% of
respondents cited the need for evidence-based clinical
information as a main barrier to their use of genetic
testing. Translational research is needed to provide more
robust data for evaluating clinical utility and best prac-
tices for adoption and implementation within Canada’s
healthcare system. Furthermore, resources that provide
physicians with easy access to accurate and current
information would certainly facilitate appropriate and
efﬁcient adoption of PM.
Conclusions
In the absence of baseline data on provider knowledge
and the practice of PM in Canada, our study ﬁlls this
important gap by providing a foundation upon which we
can build. Canada is lagging behind other jurisdictions
which have more resources in place to support PM,
including those that facilitate provider and public
understanding. PM based on genetic testing is currently
being practiced in Canada across specialties and prov-
inces. Many physician respondents recognise its beneﬁts
and appear to be open to its adoption. They report that
patients are asking them about genetic testing and PM;
however, most physician respondents are not conﬁdent
in discussing genetic testing and PM with their patients.
This may not be surprising considering the overall lack of
formal education in the ﬁeld among surveyed physicians,
as well as the limited time and resources available for
physicians to study this subject. These study results also
indicate variability in practice and access to genetic tests
across Canada among those surveyed. In addition, the
study results point to the need for pan-Canadian strate-
gies and resources that facilitate healthcare provider
knowledge, training and practice at the undergraduate
and graduate levels, and through targeted continuing
professional education interventions.
Soaring healthcare costs across industrialised coun-
tries are not sustainable. A few PM pioneers are paving
the way towards demonstrating that these new molecular
tests may result in better care at lower costs. Indeed, the
history of innovation across many industries such as the
computer, telecommunications, higher education,
transportation and many other sectors has shown that
previously inaccessible and expensive products and
services can be made more accessible at lower cost.
43
Hence, as we strive for better healthcare, PM and the
new models required for its full implementation present
an unavoidable challenge and perhaps an opportunity to
transform our healthcare system into one adapted to the
21st century.
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